Comparison · NCT01582854-sae
Actovegin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Actovegin vs Placebo: serious adverse events. Trial comparisons, record NCT01582854-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01582854-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.088 | 0.0588 | 0.13 | wilson | |
| Risk in group 2 | 0.0672 | 0.0424 | 0.105 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0208 | -0.0269 | 0.0693 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 0.713 | 2.41 | log | |
| Odds ratio, group 1 over group 2 | 1.34 | 0.693 | 2.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Actovegin than on Placebo | 48.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Actovegin | Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months. | 22 | 250 | EG000 |
| Group 2 | Placebo | Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months. | 17 | 253 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- First dose of study drug to 10 days after last dose of study drug (up to approximately 6.5 months).
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
- NCT number
- NCT01582854
- Phases
- PHASE3
- Conditions
- Post-Stroke Cognitive Impairment (PSCI)
- Interventions
- Actovegin, Placebo
- Lead sponsor
- Takeda
- Results first posted
- 2016-02-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01582854?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01582854-sae